We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Oracle (ORCL) Rolls Out New Capabilities to Enhance Database
Read MoreHide Full Article
Oracle (ORCL - Free Report) recently introduced “Autonomous Database Dedicated service.” The implementation of the new offering enables enterprise customers shift database workloads to autonomous cloud seamlessly in a secure and reliable infrastructure.
Notably, the latest service utilizes Oracle Cloud platform’s Exadata Infrastructure, which offers high workload isolation, security and performance functionalities.
Additionally, the company rolled out innovative capabilities, including Oracle SQL Developer Web, Oracle Application Express (APEX), and Oracle REST Data Services. The latest services are aimed at enabling developers to design and implement robust data-driven applications.
The latest capabilities favor adoption of Oracle Database. In fact, Jasci, an order management software and cloud warehouse provider, is utilizing Oracle Database and Oracle Cloud to enhance performance.
Past Month Price Performance
An expanding customer base is instilling confidence in this Zacks Rank #2 (Buy) stock. Notably, shares of Oracle have returned approximately 9.4% in the past month, outperforming the industry’s rally of 3.9%. In the same period, the stock has outperformed S&P 500 index’s growth of 3.8%.
Tactical Portfolio Expansion Approach to Boost Adoption
Oracle is strategically expanding Autonomous Database portfolio by incorporating robust machine learning capabilities. It enables the company to aid customers with personalized automated database services, accelerating their business processes.
Markedly, Oracle’s Database services running on the company’s public cloud platform, lowers costing and pricing parameters of its offerings. This provides the company an edge in the Database-as-a-Service market and reinforces its competitive position against Amazon’s (AMZN - Free Report) cloud computing platform, Amazon Web Services.
Oracle is leaving no stone unturned to enhance functionalities of cloud-based applications and its autonomous database, which bode well. At Oracle’s Analytics Summit, the company recently made a slew of additions to Oracle Analytics Cloud Platform suite of services. Oracle also entered into a partnership with Microsoft (MSFT - Free Report) , which is expected to enhance the companies’ presence in the enterprise cloud market.
We expect the adoption of new database services and latest cloud-based offerings to generate incremental revenues for the company in the days ahead. Moreover, synergies from Micrsoft Azure partnership are likely to act as a tailwind.
Growth Prospects Aplenty
Increasing spending on public cloud platforms and growing clout of digital transformation favor the initiatives taken by Oracle to strengthen its database and cloud platform.
Per IDC data, global spending on public cloud services and related infrastructure is envisioned to hit $210 billion in 2019, up 23.8% over 2018. Moreover, per a MarketsandMarkets report, digital transformation market is projected to hit $665 billion by 2023 at a CAGR of 18.1% from $290 billion in 2018.
We believe the company is well poised to capitalize on growth opportunities of its domain on the back of its ongoing efforts in the domain.
Long-term earnings growth rate for Rosetta Stone is pegged at 12.5%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
Image: Bigstock
Oracle (ORCL) Rolls Out New Capabilities to Enhance Database
Oracle (ORCL - Free Report) recently introduced “Autonomous Database Dedicated service.” The implementation of the new offering enables enterprise customers shift database workloads to autonomous cloud seamlessly in a secure and reliable infrastructure.
Notably, the latest service utilizes Oracle Cloud platform’s Exadata Infrastructure, which offers high workload isolation, security and performance functionalities.
Additionally, the company rolled out innovative capabilities, including Oracle SQL Developer Web, Oracle Application Express (APEX), and Oracle REST Data Services. The latest services are aimed at enabling developers to design and implement robust data-driven applications.
The latest capabilities favor adoption of Oracle Database. In fact, Jasci, an order management software and cloud warehouse provider, is utilizing Oracle Database and Oracle Cloud to enhance performance.
Past Month Price Performance
An expanding customer base is instilling confidence in this Zacks Rank #2 (Buy) stock. Notably, shares of Oracle have returned approximately 9.4% in the past month, outperforming the industry’s rally of 3.9%. In the same period, the stock has outperformed S&P 500 index’s growth of 3.8%.
Tactical Portfolio Expansion Approach to Boost Adoption
Oracle is strategically expanding Autonomous Database portfolio by incorporating robust machine learning capabilities. It enables the company to aid customers with personalized automated database services, accelerating their business processes.
Markedly, Oracle’s Database services running on the company’s public cloud platform, lowers costing and pricing parameters of its offerings. This provides the company an edge in the Database-as-a-Service market and reinforces its competitive position against Amazon’s (AMZN - Free Report) cloud computing platform, Amazon Web Services.
Oracle is leaving no stone unturned to enhance functionalities of cloud-based applications and its autonomous database, which bode well. At Oracle’s Analytics Summit, the company recently made a slew of additions to Oracle Analytics Cloud Platform suite of services. Oracle also entered into a partnership with Microsoft (MSFT - Free Report) , which is expected to enhance the companies’ presence in the enterprise cloud market.
We expect the adoption of new database services and latest cloud-based offerings to generate incremental revenues for the company in the days ahead. Moreover, synergies from Micrsoft Azure partnership are likely to act as a tailwind.
Growth Prospects Aplenty
Increasing spending on public cloud platforms and growing clout of digital transformation favor the initiatives taken by Oracle to strengthen its database and cloud platform.
Per IDC data, global spending on public cloud services and related infrastructure is envisioned to hit $210 billion in 2019, up 23.8% over 2018. Moreover, per a MarketsandMarkets report, digital transformation market is projected to hit $665 billion by 2023 at a CAGR of 18.1% from $290 billion in 2018.
We believe the company is well poised to capitalize on growth opportunities of its domain on the back of its ongoing efforts in the domain.
Another Pick
Another top-ranked stock worth considering in the same industry is Rosetta Stone Inc. , sporting Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.
Long-term earnings growth rate for Rosetta Stone is pegged at 12.5%.
Breakout Biotech Stocks with Triple-Digit Profit Potential
The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.
Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.
See these 7 breakthrough stocks now>>